Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: Individualized breast cancer prevention

James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura, Richard M. Weinshilboum

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The selective estrogen receptor modulators (SERM) tamoxifen and raloxifene can reduce the occurrence of breast cancer in high-risk women by 50%, but this U.S. Food and Drug Administration-approved prevention therapy is not often used. We attempted to identify genetic factors that contribute to variation in SERM breast cancer prevention, using DNA from the NSABP P-1 and P-2 breast cancer prevention trials. An initial discovery genome-wide association study identified common single-nucleotide polymorphisms (SNP) in or near the ZNF423 and CTSO genes that were associated with breast cancer risk during SERM therapy. We then showed that both ZNF423 and CTSO participated in the estrogen-dependent induction of BRCA1 expression, in both cases with SNPdependent variation in induction. ZNF423 appeared to be an estrogen-inducible BRCA1 transcription factor. The OR for differences in breast cancer risk during SERM therapy for subjects homozygous for both protective or both risk alleles for ZNF423 and CTSO was 5.71. SIGNIFICANCE: This study identified novel, functionally polymorphic genes involved in the estrogendependent regulation of BRCA1 expression, as well as a novel mechanism for genetic variation in SERM therapeutic effect. These observations, and definition of their underlying mechanisms, represent steps toward pharmacogenomically individualized SERM breast cancer prevention.

Original languageEnglish
Pages (from-to)812-825
Number of pages14
JournalCancer Discovery
Volume3
Issue number7
DOIs
Publication statusPublished - 01-07-2013
Externally publishedYes

Fingerprint

Selective Estrogen Receptor Modulators
Pharmacogenetics
Breast Neoplasms
Estrogens
Genome-Wide Association Study
Therapeutic Uses
United States Food and Drug Administration
Tamoxifen
Genes
Single Nucleotide Polymorphism
Transcription Factors
Therapeutics
Alleles
DNA

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Ingle, James N. ; Liu, Mohan ; Lawrence Wickerham, D. ; Schaid, Daniel J. ; Wang, Liewei ; Mushiroda, Taisei ; Kubo, Michiaki ; Costantino, Joseph P. ; Vogel, Victor G. ; Paik, Soonmyung ; Goetz, Matthew P. ; Ames, Matthew M. ; Jenkins, Gregory D. ; Batzler, Anthony ; Carlson, Erin E. ; Flockhart, David A. ; Wolmark, Norman ; Nakamura, Yusuke ; Weinshilboum, Richard M. / Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression : Individualized breast cancer prevention. In: Cancer Discovery. 2013 ; Vol. 3, No. 7. pp. 812-825.
@article{4c53feb45d424ea8bbf9a2d0113294b9,
title = "Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: Individualized breast cancer prevention",
abstract = "The selective estrogen receptor modulators (SERM) tamoxifen and raloxifene can reduce the occurrence of breast cancer in high-risk women by 50{\%}, but this U.S. Food and Drug Administration-approved prevention therapy is not often used. We attempted to identify genetic factors that contribute to variation in SERM breast cancer prevention, using DNA from the NSABP P-1 and P-2 breast cancer prevention trials. An initial discovery genome-wide association study identified common single-nucleotide polymorphisms (SNP) in or near the ZNF423 and CTSO genes that were associated with breast cancer risk during SERM therapy. We then showed that both ZNF423 and CTSO participated in the estrogen-dependent induction of BRCA1 expression, in both cases with SNPdependent variation in induction. ZNF423 appeared to be an estrogen-inducible BRCA1 transcription factor. The OR for differences in breast cancer risk during SERM therapy for subjects homozygous for both protective or both risk alleles for ZNF423 and CTSO was 5.71. SIGNIFICANCE: This study identified novel, functionally polymorphic genes involved in the estrogendependent regulation of BRCA1 expression, as well as a novel mechanism for genetic variation in SERM therapeutic effect. These observations, and definition of their underlying mechanisms, represent steps toward pharmacogenomically individualized SERM breast cancer prevention.",
author = "Ingle, {James N.} and Mohan Liu and {Lawrence Wickerham}, D. and Schaid, {Daniel J.} and Liewei Wang and Taisei Mushiroda and Michiaki Kubo and Costantino, {Joseph P.} and Vogel, {Victor G.} and Soonmyung Paik and Goetz, {Matthew P.} and Ames, {Matthew M.} and Jenkins, {Gregory D.} and Anthony Batzler and Carlson, {Erin E.} and Flockhart, {David A.} and Norman Wolmark and Yusuke Nakamura and Weinshilboum, {Richard M.}",
year = "2013",
month = "7",
day = "1",
doi = "10.1158/2159-8290.CD-13-0038",
language = "English",
volume = "3",
pages = "812--825",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

Ingle, JN, Liu, M, Lawrence Wickerham, D, Schaid, DJ, Wang, L, Mushiroda, T, Kubo, M, Costantino, JP, Vogel, VG, Paik, S, Goetz, MP, Ames, MM, Jenkins, GD, Batzler, A, Carlson, EE, Flockhart, DA, Wolmark, N, Nakamura, Y & Weinshilboum, RM 2013, 'Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: Individualized breast cancer prevention', Cancer Discovery, vol. 3, no. 7, pp. 812-825. https://doi.org/10.1158/2159-8290.CD-13-0038

Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression : Individualized breast cancer prevention. / Ingle, James N.; Liu, Mohan; Lawrence Wickerham, D.; Schaid, Daniel J.; Wang, Liewei; Mushiroda, Taisei; Kubo, Michiaki; Costantino, Joseph P.; Vogel, Victor G.; Paik, Soonmyung; Goetz, Matthew P.; Ames, Matthew M.; Jenkins, Gregory D.; Batzler, Anthony; Carlson, Erin E.; Flockhart, David A.; Wolmark, Norman; Nakamura, Yusuke; Weinshilboum, Richard M.

In: Cancer Discovery, Vol. 3, No. 7, 01.07.2013, p. 812-825.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression

T2 - Individualized breast cancer prevention

AU - Ingle, James N.

AU - Liu, Mohan

AU - Lawrence Wickerham, D.

AU - Schaid, Daniel J.

AU - Wang, Liewei

AU - Mushiroda, Taisei

AU - Kubo, Michiaki

AU - Costantino, Joseph P.

AU - Vogel, Victor G.

AU - Paik, Soonmyung

AU - Goetz, Matthew P.

AU - Ames, Matthew M.

AU - Jenkins, Gregory D.

AU - Batzler, Anthony

AU - Carlson, Erin E.

AU - Flockhart, David A.

AU - Wolmark, Norman

AU - Nakamura, Yusuke

AU - Weinshilboum, Richard M.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - The selective estrogen receptor modulators (SERM) tamoxifen and raloxifene can reduce the occurrence of breast cancer in high-risk women by 50%, but this U.S. Food and Drug Administration-approved prevention therapy is not often used. We attempted to identify genetic factors that contribute to variation in SERM breast cancer prevention, using DNA from the NSABP P-1 and P-2 breast cancer prevention trials. An initial discovery genome-wide association study identified common single-nucleotide polymorphisms (SNP) in or near the ZNF423 and CTSO genes that were associated with breast cancer risk during SERM therapy. We then showed that both ZNF423 and CTSO participated in the estrogen-dependent induction of BRCA1 expression, in both cases with SNPdependent variation in induction. ZNF423 appeared to be an estrogen-inducible BRCA1 transcription factor. The OR for differences in breast cancer risk during SERM therapy for subjects homozygous for both protective or both risk alleles for ZNF423 and CTSO was 5.71. SIGNIFICANCE: This study identified novel, functionally polymorphic genes involved in the estrogendependent regulation of BRCA1 expression, as well as a novel mechanism for genetic variation in SERM therapeutic effect. These observations, and definition of their underlying mechanisms, represent steps toward pharmacogenomically individualized SERM breast cancer prevention.

AB - The selective estrogen receptor modulators (SERM) tamoxifen and raloxifene can reduce the occurrence of breast cancer in high-risk women by 50%, but this U.S. Food and Drug Administration-approved prevention therapy is not often used. We attempted to identify genetic factors that contribute to variation in SERM breast cancer prevention, using DNA from the NSABP P-1 and P-2 breast cancer prevention trials. An initial discovery genome-wide association study identified common single-nucleotide polymorphisms (SNP) in or near the ZNF423 and CTSO genes that were associated with breast cancer risk during SERM therapy. We then showed that both ZNF423 and CTSO participated in the estrogen-dependent induction of BRCA1 expression, in both cases with SNPdependent variation in induction. ZNF423 appeared to be an estrogen-inducible BRCA1 transcription factor. The OR for differences in breast cancer risk during SERM therapy for subjects homozygous for both protective or both risk alleles for ZNF423 and CTSO was 5.71. SIGNIFICANCE: This study identified novel, functionally polymorphic genes involved in the estrogendependent regulation of BRCA1 expression, as well as a novel mechanism for genetic variation in SERM therapeutic effect. These observations, and definition of their underlying mechanisms, represent steps toward pharmacogenomically individualized SERM breast cancer prevention.

UR - http://www.scopus.com/inward/record.url?scp=84880265900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880265900&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-13-0038

DO - 10.1158/2159-8290.CD-13-0038

M3 - Article

C2 - 23764426

AN - SCOPUS:84880265900

VL - 3

SP - 812

EP - 825

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 7

ER -